ALBERT — All Library Books, journals and Electronic Records Telegrafenberg

1

Unbekannt

High-temperature dynamic hohlraums on the pulsed power driver Z (1999)

Nash, T. J. ; Derzon, M. S. ; Chandler, G. A. ; [weitere]

American Institute of Physics

In: Physics of Plasmas. 1999; 6(5): 2023-2029. Published 1999 May 01. doi: 10.1063/1.873457.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-05-01

Print ISSN: 1070-664X

Digitale ISSN: 1089-7674

Thema: Physik

Publiziert von American Institute of Physics

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

2

Unbekannt

Phase stability for thein situgrowth of Nd1+xBa2−xCu3Oy films using pulsed-laser deposition (1999)

Cantoni, C. ; Norton, D. P. ; Kroeger, D. M. ; [weitere]

American Institute of Physics

In: Applied Physics Letters. 1999; 74(1): 96-98. Published 1999 Jan 04. doi: 10.1063/1.123162.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-01-04

Print ISSN: 0003-6951

Digitale ISSN: 1077-3118

Thema: Physik

Publiziert von American Institute of Physics

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

3

Unbekannt

Radar and optical observations of asteroid 1998 KY26 (1999)

S. J. Ostro ; P. Pravec ; L. A. Benner ; [weitere]

American Association for the Advancement of Science (AAAS)

In: Science. 285(5427): 557-60.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-07-27

Beschreibung: Observations of near-Earth asteroid 1998 KY26 shortly after its discovery reveal a slightly elongated spheroid with a diameter of about 30 meters, a composition analogous to carbonaceous chondritic meteorites, and a rotation period of 10.7 minutes, which is an order of magnitude shorter than that measured for any other solar system object. The rotation is too rapid for 1998 KY26 to consist of multiple components bound together just by their mutual gravitational attraction. This monolithic object probably is a fragment derived from cratering or collisional destruction of a much larger asteroid.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Ostro -- Pravec -- Benner -- Hudson -- Sarounova -- Hicks -- Rabinowitz -- Scotti -- Tholen -- Wolf -- Jurgens -- Thomas -- Giorgini -- Chodas -- Yeomans -- Rose -- Frye -- Rosema -- Winkler -- Slade -- New York, N.Y. -- Science. 1999 Jul 23;285(5427):557-60.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109-8099, USA. Astronomical Institute, Academy of Sciences of the Czech Republic, CZ-25165 Ond&rbreve;ejov, Czech Republic. School of Electrical Engineering and.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10417379" target="_blank"〉PubMed〈/a〉

Print ISSN: 0036-8075

Digitale ISSN: 1095-9203

Thema: Biologie , Chemie und Pharmazie , Informatik , Medizin , Allgemeine Naturwissenschaft , Physik

Publiziert von American Association for the Advancement of Science (AAAS)

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

4

Unbekannt

Nonlinear evolution of broad-bandwidth, laser-imprinted nonuniformities in planar targets accelerated by 351-nm laser light (1999)

Smalyuk, V. A. ; Boehly, T. R. ; Bradley, D. K. ; [weitere]

American Institute of Physics

In: Physics of Plasmas. 1999; 6(10): 4022-4036. Published 1999 Oct 01. doi: 10.1063/1.873665.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-10-01

Print ISSN: 1070-664X

Digitale ISSN: 1089-7674

Thema: Physik

Publiziert von American Institute of Physics

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

5

Unbekannt

Nonlinear Optics for High-Speed Digital Information Processing (1999)

D. Cotter ; R. J. Manning ; K. J. Blow ; [weitere]

American Association for the Advancement of Science (AAAS)

In: Science. 286(5444): 1523-1528.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-11-24

Beschreibung: Recent advances in developing nonlinear optical techniques for processing serial digital information at high speed are reviewed. The field has been transformed by the advent of semiconductor nonlinear devices capable of operation at 100 gigabits per second and higher, well beyond the current speed limits of commercial electronics. These devices are expected to become important in future high-capacity communications networks by allowing digital regeneration and other processing functions to be performed on data signals "on the fly" in the optical domain.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Cotter -- Manning -- Blow -- Ellis -- Kelly -- Nesset -- Phillips -- Poustie -- Rogers -- New York, N.Y. -- Science. 1999 Nov 19;286(5444):1523-1528.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉BT Advanced Communications Technology Centre, Adastral Park, Martlesham Heath, Ipswich IP5 3RE, United Kingdom. Electronic Engineering, Aston University, Aston Triangle, Birmingham, B4 7ET, United Kingdom.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10567251" target="_blank"〉PubMed〈/a〉

Print ISSN: 0036-8075

Digitale ISSN: 1095-9203

Thema: Biologie , Chemie und Pharmazie , Informatik , Medizin , Allgemeine Naturwissenschaft , Physik

Publiziert von American Association for the Advancement of Science (AAAS)

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

6

Unbekannt

Peptide antagonists of the human estrogen receptor (1999)

J. D. Norris ; L. A. Paige ; D. J. Christensen ; [weitere]

American Association for the Advancement of Science (AAAS)

In: Science. 285(5428): 744-6.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-07-31

Beschreibung: Estrogen receptor alpha transcriptional activity is regulated by distinct conformational states that are the result of ligand binding. Phage display was used to identify peptides that interact specifically with either estradiol- or tamoxifen-activated estrogen receptor alpha. When these peptides were coexpressed with estrogen receptor alpha in cells, they functioned as ligand-specific antagonists, indicating that estradiol-agonist and tamoxifen-partial agonist activities do not occur by the same mechanism. The ability to regulate estrogen receptor alpha transcriptional activity by targeting sites outside of the ligand-binding pocket has implications for the development of estrogen receptor alpha antagonists for the treatment of tamoxifen-refractory breast cancers.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Norris, J D -- Paige, L A -- Christensen, D J -- Chang, C Y -- Huacani, M R -- Fan, D -- Hamilton, P T -- Fowlkes, D M -- McDonnell, D P -- DK48807/DK/NIDDK NIH HHS/ -- New York, N.Y. -- Science. 1999 Jul 30;285(5428):744-6.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Duke University Medical Center, Department of Pharmacology and Cancer Biology, Durham, NC 27710, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10426998" target="_blank"〉PubMed〈/a〉

Schlagwort(e): Amino Acid Sequence ; Binding Sites ; Estradiol/metabolism/*pharmacology ; Estrogen Antagonists/*pharmacology ; Estrogen Receptor alpha ; Humans ; Ligands ; Mifepristone/pharmacology ; Molecular Sequence Data ; Peptide Library ; Peptides/metabolism/*pharmacology ; Receptors, Cytoplasmic and Nuclear/metabolism ; Receptors, Estrogen/agonists/*antagonists & inhibitors/chemistry/*metabolism ; Recombinant Fusion Proteins/pharmacology ; Tamoxifen/metabolism/*pharmacology ; Transcription Factor AP-1/genetics/metabolism ; Transcription, Genetic/drug effects

Print ISSN: 0036-8075

Digitale ISSN: 1095-9203

Thema: Biologie , Chemie und Pharmazie , Informatik , Medizin , Allgemeine Naturwissenschaft , Physik

Publiziert von American Association for the Advancement of Science (AAAS)

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

7

Unbekannt

Receptor for motilin identified in the human gastrointestinal system (1999)

S. D. Feighner ; C. P. Tan ; K. K. McKee ; [weitere]

American Association for the Advancement of Science (AAAS)

In: Science. 284(5423): 2184-8.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-06-26

Beschreibung: Motilin is a 22-amino acid peptide hormone expressed throughout the gastrointestinal (GI) tract of humans and other species. It affects gastric motility by stimulating interdigestive antrum and duodenal contractions. A heterotrimeric guanosine triphosphate-binding protein (G protein)-coupled receptor for motilin was isolated from human stomach, and its amino acid sequence was found to be 52 percent identical to the human receptor for growth hormone secretagogues. The macrolide antibiotic erythromycin also interacted with the cloned motilin receptor, providing a molecular basis for its effects on the human GI tract. The motilin receptor is expressed in enteric neurons of the human duodenum and colon. Development of motilin receptor agonists and antagonists may be useful in the treatment of multiple disorders of GI motility.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Feighner, S D -- Tan, C P -- McKee, K K -- Palyha, O C -- Hreniuk, D L -- Pong, S S -- Austin, C P -- Figueroa, D -- MacNeil, D -- Cascieri, M A -- Nargund, R -- Bakshi, R -- Abramovitz, M -- Stocco, R -- Kargman, S -- O'Neill, G -- Van Der Ploeg, L H -- Evans, J -- Patchett, A A -- Smith, R G -- Howard, A D -- New York, N.Y. -- Science. 1999 Jun 25;284(5423):2184-8.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Metabolic Disorders, Department of Medicinal Chemistry, Merck Research Laboratories, Building RY-80Y-265, 126 East Lincoln Avenue, Rahway, NJ 07065, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10381885" target="_blank"〉PubMed〈/a〉

Schlagwort(e): Alternative Splicing ; Amino Acid Sequence ; Base Sequence ; Binding Sites ; Calcium/metabolism ; Cell Line ; Chromosome Mapping ; Chromosomes, Human, Pair 13 ; Cloning, Molecular ; Colon/*metabolism ; Erythromycin/metabolism ; GTP-Binding Proteins/metabolism ; Humans ; In Situ Hybridization ; Intestine, Small/*metabolism ; Ligands ; Molecular Sequence Data ; Motilin/analogs & derivatives/*metabolism ; Receptors, Gastrointestinal Hormone/*chemistry/*genetics/metabolism ; Receptors, Neuropeptide/*chemistry/*genetics/metabolism ; Stomach/*metabolism ; Thyroid Gland/metabolism ; Transfection

Print ISSN: 0036-8075

Digitale ISSN: 1095-9203

Thema: Biologie , Chemie und Pharmazie , Informatik , Medizin , Allgemeine Naturwissenschaft , Physik

Publiziert von American Association for the Advancement of Science (AAAS)

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

8

Unbekannt

Investigation of tritium pathways in the Joint European Torus (JET) tokamak (1999)

Hillis, D. L. ; Hogan, J. T. ; Andrew, P. ; [weitere]

American Institute of Physics

In: Physics of Plasmas. 1999; 6(5): 1985-1994. Published 1999 May 01. doi: 10.1063/1.873454.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-05-01

Print ISSN: 1070-664X

Digitale ISSN: 1089-7674

Thema: Physik

Publiziert von American Institute of Physics

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

9

Unbekannt

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma (1999)

Barlogie, B. ; Jagannath, S. ; Desikan, K.R. ; [weitere]

American Society of Hematology

In: Blood. 1999; 93(1): 55-65. Published 1999 Jan 01. doi: 10.1182/blood.v93.1.55.401k04_55_65.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-01-01

Beschreibung: Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of induction regimens and two cycles of high-dose therapy (“Total Therapy”). Remission induction utilized non–cross-resistant regimens (vincristine-doxorubicin-dexamethasone [VAD], high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dexamethasone-cytarabine-cisplatin). The first high-dose treatment comprised melphalan 200 mg/m2 and was repeated if complete (CR) or partial (PR) remission was maintained after the first transplant; in case of less than PR, total body irradiation or cyclophosphamide was added. Interferon--2b maintenance was used after the second autotransplant. Fourteen patients with HLA-compatible donors underwent an allograft as their second high-dose therapy cycle. Eighty-eight percent completed induction therapy whereas first and second transplants were performed in 84% and 71% (the majority within 8 and 15 months, respectively). Eight patients (3%) died of toxicity during induction, and 2 (1%) and 6 (4%) during the two transplants. True CR and at least a PR (PR plus CR) were obtained in 5% (34%) after VAD, 15% (65%) at the end of induction, and 26% (75%) after the first and 41% (83%) after the second transplants (intent-to-treat). Median overall (OS) and event-free (EFS) survival durations were 68 and 43 months, respectively. Actuarial 5-year OS and EFS rates were 58% and 42%, respectively. The median time to disease progression or relapse was 52 months. Among the 94 patients achieving CR, the median CR duration was 50 months. On multivariate analysis, superior EFS and OS were observed in the absence of unfavorable karyotypes (11q breakpoint abnormalities, -13 or 13-q) and with low β-2-microglobulin at diagnosis. CR duration was significantly longer with early onset of CR and favorable karyotypes. Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and β-2-microglobulin. Total Therapy represents a comprehensive treatment approach for newly diagnosed myeloma patients, using multi-regimen induction and tandem transplantation followed by interferon maintenance. As a result, the proportion of patients attaining CR increased progressively with continuing therapy. This observation is particularly important because CR is a sine qua non for long-term disease control and, eventually, cure.

Print ISSN: 0006-4971

Digitale ISSN: 1528-0020

Thema: Biologie , Medizin

Publiziert von American Society of Hematology

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext

10

Unbekannt

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma (1999)

Barlogie, B. ; Jagannath, S. ; Desikan, K.R. ; [weitere]

American Society of Hematology

In: Blood. 1999; 93(1): 55-65. Published 1999 Jan 01. doi: 10.1182/blood.v93.1.55.

zur Merkliste hinzufügen auf der Merkliste

Details

Publikationsdatum: 1999-01-01

Beschreibung: Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of induction regimens and two cycles of high-dose therapy (“Total Therapy”). Remission induction utilized non–cross-resistant regimens (vincristine-doxorubicin-dexamethasone [VAD], high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dexamethasone-cytarabine-cisplatin). The first high-dose treatment comprised melphalan 200 mg/m2 and was repeated if complete (CR) or partial (PR) remission was maintained after the first transplant; in case of less than PR, total body irradiation or cyclophosphamide was added. Interferon--2b maintenance was used after the second autotransplant. Fourteen patients with HLA-compatible donors underwent an allograft as their second high-dose therapy cycle. Eighty-eight percent completed induction therapy whereas first and second transplants were performed in 84% and 71% (the majority within 8 and 15 months, respectively). Eight patients (3%) died of toxicity during induction, and 2 (1%) and 6 (4%) during the two transplants. True CR and at least a PR (PR plus CR) were obtained in 5% (34%) after VAD, 15% (65%) at the end of induction, and 26% (75%) after the first and 41% (83%) after the second transplants (intent-to-treat). Median overall (OS) and event-free (EFS) survival durations were 68 and 43 months, respectively. Actuarial 5-year OS and EFS rates were 58% and 42%, respectively. The median time to disease progression or relapse was 52 months. Among the 94 patients achieving CR, the median CR duration was 50 months. On multivariate analysis, superior EFS and OS were observed in the absence of unfavorable karyotypes (11q breakpoint abnormalities, -13 or 13-q) and with low β-2-microglobulin at diagnosis. CR duration was significantly longer with early onset of CR and favorable karyotypes. Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and β-2-microglobulin. Total Therapy represents a comprehensive treatment approach for newly diagnosed myeloma patients, using multi-regimen induction and tandem transplantation followed by interferon maintenance. As a result, the proportion of patients attaining CR increased progressively with continuing therapy. This observation is particularly important because CR is a sine qua non for long-term disease control and, eventually, cure.

Print ISSN: 0006-4971

Digitale ISSN: 1528-0020

Thema: Biologie , Medizin

Publiziert von American Society of Hematology

Permalink

	Standort	Signatur	Erwartet	Verfügbarkeit

Andere fanden auch interessant ...

AKTUELLE ARTIKEL

S·F·X

Volltext